New Delhi, June 6: CSIR India and Laxai Life Sciences private limited have initiated phase II clinical trial with anti-helminitic drug Niclosamide for treatment of Covid-19, officials said on Sunday.
The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients, they added.
Niclosamide has been extensively used in past for treatment of tapeworm’s infection in adults as well as children. The safety profile of this drug has been tested over time and has been found safe for human consumption at different dose levels.
Dr Shekhar C Mande, Director General, CSIR expressed his happiness over the SEC recommendations to conduct this Phase II clinical trial using Niclosamide, which is generic, affordable drug and easily available in India and therefore can be made available to our population.